TheraRadar
Clinical-Stage Companies / Clover Biopharmaceuticals AUS

Clover Biopharmaceuticals AUS

Pre-Approval PRO BETA
16
Total Trials
6
Phase 3
4
Phase 2
1
Recruiting
154
Score

Pipeline by Phase

Phase 3
6
Phase 2
4
Phase 1
9

Therapeutic Focus

COVID-19 RSV Infection Human Metapneumovirus Infection Parainfluenza Infection Respiratory Syncytial Virus Vaccination

Clinical Trials (16)

NCT06567457 Phase 3 WITHDRAWN

Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults

Started: 10/1/2023

NCT05926440 Phase 3 WITHDRAWN

Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults

Started: 8/17/2023

NCT05188677 Phase 3 COMPLETED

Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

Started: 6/13/2022

NCT05012787 Phase 3 TERMINATED

Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases

Started: 11/12/2021

NCT04672395 Phase 2 COMPLETED

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

Started: 3/24/2021

NCT05193279 Phase 2 WITHDRAWN

Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

Started: 10/5/2022

NCT04950751 Phase 2 WITHDRAWN

Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults

Started: 8/1/2021

NCT06984094 Phase 1 ACTIVE NOT RECRUITING

Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

Started: 6/18/2025

NCT06194318 Phase 1 COMPLETED

First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

Started: 12/13/2023

NCT06666179 Phase 1 WITHDRAWN

Safety and Immunogenicity Study of SCB-1019T in Children

Started: 10/1/2025

NCT05228314 Phase 1 COMPLETED

Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults

Started: 5/30/2022

NCT04919096 Phase 1 WITHDRAWN

Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration

Started: 4/1/2022

NCT04405908 Phase 1 COMPLETED

SCB-2019 as COVID-19 Vaccine

Started: 6/19/2020

NCT04932824 Phase 1 COMPLETED

Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.

Started: 1/19/2021

NCT03869697 Phase 1 COMPLETED

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

Started: 11/20/2019

NCT03443674 Phase 1 COMPLETED

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

Started: 6/18/2018

Drug Candidates

SCB-1019T SCB-1022 SCB-1033 Candidate vaccine, SCB-1019 candidate vaccine, SCB-1019T AREXVY low dose SCB-1019T adjuvanted low dose SCB-1019T high dose SCB-1019T adjuvanted high dose SCB-1019T
Activity Status: Active
Last Trial Started: 10/1/2025
Last Trial Ended: 5/7/2025
Trials (12 months): 1
Completed Trials: 8
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.